Results of traditional and new regimens of MDR/XDR TB treatment: cohort analysis Source: International Congress 2019 – Drug-resistant tuberculosis Year: 2019
Video-observed treatment for tuberculosis patients in Belarus: findings from the first programmatic experience Source: Eur Respir J , 49 (3) 1602049; DOI: 10.1183/13993003.02049-2016 Year: 2017
Pragmatic global dosing recommendations for the 3-month, once-weekly rifapentine and isoniazid preventive TB regimen in children Source: Eur Respir J, 57 (1) 2001756; 10.1183/13993003.01756-2020 Year: 2021
The effectiveness and safety of empirical anti-TB therapy in a population with high TB prevalence Source: Eur Respir J 2001; 18: Suppl. 33, 468s Year: 2001
Treatment outcomes of new cases of polyresistant pulmonary TB with second line anti-TB drugs in DOTS-Plus regimen Source: Eur Respir J 2002; 20: Suppl. 38, 359s Year: 2002
Short 12-month regimen with intravenouse linezolid for MDR-TB: treatment outcomes and first follow up results. Source: International Congress 2018 – New developments in tuberculosis Year: 2018
Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021
Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study Source: Eur Respir J, 49 (5) 1700387; 10.1183/13993003.00387-2017 Year: 2017
Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review Source: Eur Respir J, 52 (1) 1800934; 10.1183/13993003.00934-2018 Year: 2018
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009
The assessment of the efficacy of a standard chemotherapy regimen in the treatment of new sputum-positive tuberculosis (TB) patients Source: Eur Respir J 2001; 18: Suppl. 33, 340s Year: 2001
Results of the implementation of the WHO-recommended TB control strategy in Russia Source: Eur Respir J 2002; 20: Suppl. 38, 368s Year: 2002
MDR-TB guidelines: what is new on clinical management Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management Year: 2020
Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016
MDR-TB and XDR-TB: drug resistance and treatment outcomes Source: Eur Respir J 2009; 34: 778 Year: 2009
Effectiveness and safety of six month chemotherapy course of XDR TB including bedaquiline and linezolid Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016
Effectiveness and safety of standardised shorter regimens for multidrug-resistant tuberculosis: individual patient data and aggregate data meta-analyses Source: Eur Respir J, 50 (1) 1700061; 10.1183/13993003.00061-2017 Year: 2017